medmix Switzerland AG

medmix Switzerland AG has been granted 50 US utility patents between 2022 and 2025, placing medmix Switzerland AG at rank #6,729 across all assignees tracked by PlainPatent. This portfolio spans 23 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.7 claims per patent with primary concentration in B05C (APPARATUS FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL). As a Foreign Corporation, medmix Switzerland AG is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 60.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Historical data spans 2022 through 2025, with 50 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. medmix Switzerland AG's 16.7 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 23 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark medmix Switzerland AG against peers pursuing similar technology classes.